E-Mindfulness Approaches for Living After Breast Cancer

This study is looking at different ways to deliver mindfulness programs to younger breast cancer survivors (diagnosed at age 50 or younger) who have finished their main cancer treatments and are experiencing symptoms of depression. You would participate in one of three groups: a live online mindfulness program (MAPs Live Online), a mindfulness app (MAPs Digital App), or a meditation-only control group. The goal is to see if these digital mindfulness programs can help improve mental health and well-being. Researchers will measure self-reported depressive symptoms two weeks after the program ends to see which approach is most effective. The study plans to enroll 402 participants.

Study design: This is a randomized study comparing two digital mindfulness programs to a meditation-only group, with 402 planned participants.
What's involved: You will participate in either a live online mindfulness program, a mindfulness app, or a meditation-only group. You will also be asked to practice mindfulness techniques at home.
Compensation: Not stated in the trial record.
Follow-up: Your depressive symptoms will be measured two weeks after the intervention ends.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

E-Mindfulness Approaches for Living After Breast Cancer

Recruiting

PHASE3Ages 18–50InterventionalPrevention

NRG Oncology

~402 participants

Updated 2026-08-04 on ClinicalTrials.gov

What's tested:Mindfulness (MAPs) Live OnlineMindfulness (MAPs) Digital AppMeditation Only Control Group

At a glance

Recruiting sites

376 of 383 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Self-reported depressive symptoms measured-post intervention in the Mindful Awareness Practices (MAPs) live online (LO) and the meditation only (MO) groups

Measured over 2 weeks post-intervention

+1 more outcome measured

Conditions

Breast Cancer

Depression

Where it's being run

383 sites across 40 states

California55

Illinois46

Pennsylvania31

Wisconsin24

Michigan23

Maryland19

North Carolina19

Ohio19

Who to contact

Director Regulatory Affairs

[email protected]

412-339-5300

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

The participant or a legally authorized representative must provide study-specific informed consent prior to pre-entry and, for participants treated in the U.S., authorization permitting release of personal health information.

The participant must have been greater than or equal to 18 or less than or equal to 50 years of age at the time of breast cancer diagnosis.

The participant must have a first-time diagnosis of non-metastatic breast cancer which is Stage 0, I, II, or III.

The participant must have a score of greater than or equal to 5 and less than or equal to 14 on the Patient Health Questionnaire-8 item (PHQ-8).

Participants must have completed all primary breast cancer treatments at least 6 months prior to and no more than 5 years prior to registration. Note: Primary treatments include surgery, radiation therapy, adjuvant chemotherapy, targeted therapies (e.g., PARP (poly-ADP ribose polymerase) inhibitors, CDK4/6 inhibitors, TDM-1, pertuzumab, or immunotherapy). (Participants may still be taking adjuvant therapy with trastuzumab or adjuvant endocrine therapy or completing minor reconstructive surgery.)

Participant must be able to understand, speak, read, and write in English or Spanish.

Participant must be willing to participate in a 6-week program to receive training in mindfulness.

Participant must be able to use a smartphone, tablet, or other digital device.

Sex assigned at birth must be female.

Exclusion

Patient Health Questionnaire-8 item (PHQ-8) score of less than 5 or greater than 14 .

Any history or current evidence of recurrent or metastatic breast cancer.

Current or past history of another cancer. Participants with a history of only non-melanoma skin cancer or in situ cervical cancer without chemotherapy treatment would be eligible.

Currently pregnant or planning to become pregnant in the near future.

Participants who are enrolled in other cancer control or behavioral intervention trials that require frequent assessments or training activities.

What this trial measures

Self-reported depressive symptoms measured-post intervention in the Mindful Awareness Practices (MAPs) live online (LO) and the meditation only (MO) groups2 weeks post-intervention
The Center for Epidemiologic Studies-Depression (CES-D) score. The score is calculated as the sum of the points for all 10 items. The score range is 0-30 and a score of 10 or greater is considered depressed.
Self-reported depressive symptoms measured-post intervention in the Mindful Awareness Practices (MAPs) App and the meditation only (MO) groups2 weeks post-intervention
The Center for Epidemiologic Studies-Depression (CES-D) score. The score is calculated as the sum of the points for all 10 items. The score range is 0-30 and a score of 10 or greater is considered depressed.

Trialytics